Big Buttons

• FDA doubles down: Tirzepatide is off shortage

  ...but that doesn't mean the issue is completely settled. read more →

• A couple of state updates

  Good news from Alabama, but a problem in Massachusetts read more →

• Defending GLP-1 compounding

  The latest letters APC's been sending to oppose efforts to restrict compounding read more →

• Thumbs-up for FDA crackdown

  APC was thrilled when the FDA announced it was taking action against illegal online businesses claiming to sell “research-grade” compounds. read more →

• A PANS/PANDAS explainer

  For your patients: Information about a couple of underdiagnosed pediatric mental health conditions read more →

• What, a year?

  In the final board chair column of the year, here are our top 7 accomplishments in 2024. read more →

• “Simply not a rational approach to regulating an industry”

  This week APC offered its final (and pointed) suggestions to the California Board of Pharmacy on their proposed significant – and we would say unjustified – changes to their compounding regulations. read more →

• Get a cease and desist letter from Verrica?

  APC has heard reports from several pharmacies that have received them — here's what to know. read more →

More News

Long-time APC partner PCCA is our newest Diamond-level Corporate Patron for
2024 and has committed additional funding to sponsor a series APC regional meetings this year.

“We treasure our strong relationship with PCCA and we’re grateful for all their support, both financial and through the expertise of their team,” said APC’s Scott Brunner. “Their increased investment this year allows us to expand the work we’re doing to protect patient access to compounded medications.”

APC also has two new Bronze-level Corporate Patrons—Medizap and Rx MediSource. You can find more information on all of our Corporate Patrons on our website.